Treatment of Adrenocortical Carcinoma - 28/10/19
, Matthew Nehs, MD b, c, Kerry Kilbridge, MD b, c, dAbstract |
Adrenocortical carcinoma (ACC) is a rare malignancy with a poor prognosis. ACC is capable of secreting excess adrenocortical hormones, which can compound morbidity and compromise clinical outcomes. By the time most ACCs are diagnosed, there is usually locoregional or metastatic disease. Surgery is the most important treatment to offer possibility of cure or prolong survival. Several adjuvant therapies are used depending on grade and stage of the tumor and other patient-related factors. This review provides an overview of treatment approaches for ACC, highlighting evidence to support each treatment and acknowledging where more data and research are needed to improve care.
Le texte complet de cet article est disponible en PDF.Keywords : Adrenocortical carcinoma, Adrenal, Mitotane, Adrenal cortex, Cancer
Plan
| Disclosures: M. Nehs and K. Kilbridge have nothing to disclose. A. Vaidya has been a consultant and/or scientific advisory board member for Corcept Therapeutics, Ionis Pharmaceuticals, Selenity Therapeutics, HRA Pharma, and Orphagen Pharmaceuticals. |
Vol 12 - N° 4
P. 997-1006 - décembre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
